Publikasi Scopus FKUI 2021 per tanggal 31 Oktober 2021 (739 artikel)

Alatas F.S., Matsuura T., Yoshimaru K., Kadim M., Taguchi T.
57217150164;8666654700;42662821300;26644177600;35428570900;
Alopecia in Children Following Living Related Liver Transplantation
2021
Transplantation Proceedings
53
1
228
232
Department of Pediatric Surgery, Reproductive and Developmental Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Child Health, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Alatas, F.S., Department of Pediatric Surgery, Reproductive and Developmental Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Department of Child Health, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Matsuura, T., Department of Pediatric Surgery, Reproductive and Developmental Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Yoshimaru, K., Department of Pediatric Surgery, Reproductive and Developmental Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Kadim, M., Department of Child Health, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Taguchi, T., Department of Pediatric Surgery, Reproductive and Developmental Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Introduction: Alopecia is a common complication in patients following kidney transplantation; however, reports regarding liver transplantation patients are still few. Methods: This study followed 111 children who underwent living related liver transplantation. Alopecia patients and its possible risk factors were analyzed. Results: Alopecia occurred in 3 patients (2.7%). Underlying diseases were biliary atresia and Alagille syndrome. Clinically significant alopecia (universal alopecia) occurred in 1 patient with Alagille syndrome. All patients received tacrolimus as their immunosuppression drug. None of the patients who received cyclosporine experienced alopecia. The onset of alopecia ranged from 7 to 28 months after transplantation. Alopecia was treated with a topical corticosteroid and topical tacrolimus, but 1 patient with clinically severe alopecia required conversion from tacrolimus to cyclosporine A. Conclusions: Alopecia is 1 complication seen in children receiving tacrolimus therapy following living donor liver transplant. Prompt management of this cosmetic complication should be done to ensure patients? compliance to medication regimen. ? 2020 Elsevier Inc.
corticosteroid; cyclosporine; methylprednisolone; mycophenolate mofetil; prednisolone; tacrolimus; thymocyte antibody; cyclosporine; immunosuppressive agent; tacrolimus; acute graft rejection; Alagille syndrome; alopecia; Article; bile duct atresia; case report; child; clinical article; comorbidity; female; human; immunosuppressive treatment; liver transplantation; living related donor; male; medication compliance; pediatric patient; risk assessment; risk factor; treatment withdrawal; adverse event; alopecia; immunocompromised patient; immunology; infant; living donor; preschool child; Alopecia; Child, Preschool; Cyclosporine; Female; Humans; Immunocompromised Host; Immunosuppression; Immunosuppressive Agents; Infant; Liver Transplantation; Living Donors; Male; Tacrolimus
Elsevier Inc.
411345
32605770
Article
Q3
373
12773